GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (OTCPK:SHPGF) » Definitions » EV-to-EBITDA

Shire (SHPGF) EV-to-EBITDA : 9.91 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Shire EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shire's enterprise value is $56,751 Mil. Shire's EBITDA for the trailing twelve months (TTM) ended in Sep. 2018 was $5,724 Mil. Therefore, Shire's EV-to-EBITDA for today is 9.91.

The historical rank and industry rank for Shire's EV-to-EBITDA or its related term are showing as below:

SHPGF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.14
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Shire's stock price is $63.00. Shire's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $5.250. Therefore, Shire's PE Ratio for today is 12.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Shire EV-to-EBITDA Historical Data

The historical data trend for Shire's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire EV-to-EBITDA Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.06 10.76 21.14 31.27 13.71

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.84 13.71 12.03 12.62 12.62

Competitive Comparison of Shire's EV-to-EBITDA

For the Biotechnology subindustry, Shire's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shire's EV-to-EBITDA falls into.



Shire EV-to-EBITDA Calculation

Shire's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=56750.630/5724.4
=9.91

Shire's current Enterprise Value is $56,751 Mil.
Shire's EBITDA for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,724 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire  (OTCPK:SHPGF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Shire's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=63.00/5.250
=12.00

Shire's share price for today is $63.00.
Shire's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.250.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Shire EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shire's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPGF) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Shire (SHPGF) Headlines

From GuruFocus

Chris Davis' Top 3 Buys of the 1st Quarter

By James Li James Li 05-14-2018

4 Stocks John Paulson and Paul Tudor Jones Agree On

By Sydnee Gatewood Sydnee Gatewood 09-21-2018

Takeda Closes In on Shire, But It's Not a Done Deal Yet

By John Engle John Engle 05-08-2018